Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report
To assess the safety of the association of radiotherapy (RT) and systemic treatments for patients with metastatic malignant melanoma (mMM).
A retrospective analysis included consecutive patients treated with palliative RT, and at least one line of systemic therapy for mMM between 2001 and 2016. Treatments were defined as sequential or concomitant when RT and the systemic drug were administered, respectively, at more or less than five half-lives from each other.
92 patients were included. They had 110 palliative RT treatments. RT was delivered with a “conventional” chemotherapy (mainly fotemustine and/or dacarbazine) and a “modern” systemic therapy (BRAF inhibitors, association of BRAF and MEK inhibitors, immunotherapy), respectively, in 88 (80%) and 22 (20%) cases. Systemic treatments and RT were mainly concurrently performed (n = 61, 55.5%). Regarding acute grade ≥ 3 toxicity, no difference was reported between sequential and concomitant groups either in the whole cohort (p = 1) or in the subgroup of patients receiving “modern” systemic therapies (p = 1). Acute and late grade ≥ 3 toxicities only occurred with vemurafenib. BRAF inhibitors and RT produced more severe infield adverse events than other associations (p = 0.001) with two deaths.
In our series, compared to sequential administration, concomitant association of systemic anticancer drugs and palliative RT did not increase toxicity in mMM patients. BRAF inhibitors and RT produced severe infield toxicities. Prospective studies are needed to better characterize the toxicity of each association.
KeywordsMelanoma Radiation therapy Systemic drugs Toxicity
Compliance with ethical standards
Conflict of interest
Authors declare having no conflict of interest.
- 1.Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, Grob J-J, Malvehy J, Newton-Bishop J, Stratigos AJ, Pehamberger H, Eggermont AM, European Dermatology Forum (EDF) et al (2016) Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline—update 2016. Eur J Cancer Oxf Engl 1990 63:201–217. https://doi.org/10.1016/j.ejca.2016.05.005 Google Scholar
- 2.Guillot B, Dalac S, Denis MG, Dupuy A, Emile JF, De La Fouchardiere A, Hindie E, Jouary T, Lassau N, Mirabel X, Piperno Neumann S, De Raucourt S, Vanwijck R (2017) French updated recommendations in Stage I to III melanoma treatment and management. J Eur Acad Dermatol Venereol 31:594–602. https://doi.org/10.1111/jdv.14064 CrossRefGoogle Scholar
- 4.Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248–1260. https://doi.org/10.1016/S1470-2045(16)30122-X CrossRefGoogle Scholar
- 5.Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30–39. https://doi.org/10.1056/NEJMoa1412690 CrossRefGoogle Scholar
- 6.Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M et al (2017) Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 28:1631–1639. https://doi.org/10.1093/annonc/mdx176 CrossRefGoogle Scholar
- 7.Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. https://doi.org/10.1056/NEJMoa1200690 CrossRefGoogle Scholar
- 8.Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330. https://doi.org/10.1056/NEJMoa1412082 CrossRefGoogle Scholar
- 9.Schachter J, Ribas A, Long GV, Arance A, Grob J-J, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390:1853–1862. https://doi.org/10.1016/S0140-6736(17)31601-X CrossRefGoogle Scholar
- 10.Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. https://doi.org/10.1056/NEJMoa1003466 CrossRefGoogle Scholar
- 11.Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain J-F, Testori A, Grob J-J, Davidson N, Richards J, Maio M et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526. https://doi.org/10.1056/NEJMoa1104621 CrossRefGoogle Scholar
- 12.Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J et al (2015) Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol 16:1049–1060. https://doi.org/10.1016/S1470-2045(15)00187-4 CrossRefGoogle Scholar
- 14.Danish HH, Patel KR, Switchenko JM, Gillespie TW, Jhaveri J, Chowdhary M, Abugideiri M, Delman KA, Lawson DH, Khan MK (2016) The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis. Melanoma Res 26:595–603. https://doi.org/10.1097/CMR.0000000000000292 CrossRefGoogle Scholar
- 16.Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM (2016) Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys 95:632–646. https://doi.org/10.1016/j.ijrobp.2016.01.038 CrossRefGoogle Scholar
- 17.Shargel L, Wu-Pong S, Yu ABC (2015) Applied biopharmaceuticals & pharmacokinetics, 7th edn. McGraw Hill MedicalGoogle Scholar
- 18.European Medicines Agency (EMA); Find Medicines. Human Medicines [Internet]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124. Accessed 20 Jan 2019
- 19.Common Terminology Criteria for Adverse Events v4.0 (CTCAE) [Internet]. http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf. Accessed 20 Jan 2019
- 21.Guadagnolo BA, Liao K-P, Elting L, Giordano S, Buchholz TA, Tina Shih Y-C (2013) Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol 31:80–87. https://doi.org/10.1200/JCO.2012.45.0585 CrossRefGoogle Scholar
- 23.Langrand-Escure J, Vallard A, Rivoirard R, Méry B, Guy J-B, Espenel S, Trone J-C, Ben Mrad M, Diao P, Rancoule C, Suchaud J-P, Fournel P, Guillot A et al (2016) Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report. Anticancer Drugs 27:427–432. https://doi.org/10.1097/CAD.0000000000000349 CrossRefGoogle Scholar
- 30.Schulze B, Meissner M, Wolter M, Rödel C, Weiss C (2014) Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. Strahlenther Onkol 190:229–232. https://doi.org/10.1007/s00066-013-0474-3 CrossRefGoogle Scholar
- 34.Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, Gleisner S, Schulze B, Goldinger SM, Berking C, Forschner A, Clemens P, Grabenbauer G et al (2015) Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol 26:1238–1244. https://doi.org/10.1093/annonc/mdv139 CrossRefGoogle Scholar
- 37.Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM (2011) Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 98:394–399. https://doi.org/10.1016/j.radonc.2010.12.017 CrossRefGoogle Scholar
- 40.Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, Chan TA, Yamada Y, Beal K (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368–375. https://doi.org/10.1016/j.ijrobp.2015.01.004 CrossRefGoogle Scholar
- 42.Schiavone MB, Broach V, Shoushtari AN, Carvajal RD, Alektiar K, Kollmeier MA, Abu-Rustum NR, Leitao MM (2016) Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecol Oncol Rep 16:42–46. https://doi.org/10.1016/j.gore.2016.04.001 CrossRefGoogle Scholar
- 44.Nomura M, Otsuka A, Yoshimura M, Nonomura Y, Kaku Y, Matsumoto S, Muto M (2018) Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab. Cancer Chemother Pharmacol 81:823–827. https://doi.org/10.1007/s00280-018-3557-0 CrossRefGoogle Scholar
- 45.Ahmed KA, Stallworth DG, Kim Y, Johnstone PS, Harrison LB, Caudell JJ, Yu HHM, Etame AB, Weber JS, Gibney GT (2016) Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 27:434–441. https://doi.org/10.1093/annonc/mdv622 CrossRefGoogle Scholar